Matheson


News and Insights

Print this page

Search News & Insights


Matheson advises Royalty Pharma on revised $6.5 billion hostile bid for Elan

AUTHOR(S): Tim Scanlon, George Brady, Fergus Bolster
PRACTICE AREA GROUP: Corporate
DATE: 21.05.2013

Matheson continues to advise Royalty Pharma on its $6.5 billion cash offer for Elan Corporation plc, the Irish biotechnology company. On 20 May 2013, Royalty Pharma revised its hostile offer for the NASDAQ-listed Elan Corporation.

The Matheson team is led by Tim Scanlon, George Brady and Fergus Bolster.

This is the latest in a number of high-profile multi-billion dollar transactions that Matheson has advised on. 

Matheson is also advising the US pharmaceutical firm Actavis on its $5.1 billion acquisition of Dublin-based Warner Chilcott. The all-stock deal was announced on 20 May 2013 and the acquisition is expected to be completed by the end of the year.

In February of this year, Matheson advised on the sale of the country's biggest life and pensions provider Irish Life to Canada Life parent, Great-West Lifeco. The firm advised Ireland's Minister for Finance on the €1.3 billion sale, which has been described as a "historic transaction."

Matheson recently advised Eaton Corporation plc on its $11.8 billion acquisition of Cooper Industries. This was the largest single M&A transaction in Ireland during 2012 and was named 'Most Innovative Deal of the Year' at the Finance Dublin 2013 Awards.

Matheson is the law firm of choice for international companies and financial institutions doing business in and through Ireland.

BACK TO LISTING

Matheson Snapshot


About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)